Skip to main content
. 2020 Jan 5;7(1):117–122. doi: 10.1002/ehf2.12533

Table 1.

Baseline characteristics across PCSK9 values

Variables

PCSK9 below median

(<1.94 U/mL)

(n = 20)

PCSK9 above median

(>1.94 U/mL)

(n = 20)

P
Demographics and medical history
Age (years) 59 ± 12 60 ± 12 0.638
Male, n (%) 17 (85) 16 (80) 0.677
Hypertension, n (%) 12 (60) 10 (50) 0.525
Diabetes mellitus, n (%) 4 (20) 4 (20) 1
Dyslipidemia, n (%) 4 (20) 11 (55) 0.022
Smoker, n (%) 13 (65) 11 (55) 0.519
Anterior infarction, n (%) 15 (75) 12 (60) 0.311
GRACE score 137 ± 28 147 ± 38 0.321
TIMI risk scorea 3 (1.5–4) 2 (1.5–3.5) 0.499
Laboratory data
Killip class ≥ II, n (%) 6 (30) 3 (15) 0.256
Peak hsTnT (ng/mL)a 3631 (1772–4987) 3702 (2892–7627) 0.159
ST2 (pg/mL)a 86.7 (37.9–113.8) 103.9 (63.2–135.9) 0.083
PCSK9 (U/mL) 1.64 ± 0.25 2.22 ± 0.23 <0.001
CMR at 1 week
LVEF (%) 42 ± 7 41 ± 7 0.641
LVEDVI (mL/m2) 84 ± 18 78 ± 20 0.445
LVESVI (mL/m2) 48 ± 11 48 ± 17 0.953
Infarct size (%)a 28 (19–34) 30 (26–41) 0.206
MVO (%) 2.1 ± 0.4 2.6 ± 0.6 0.482
Medical treatment at discharge
Aldosterone receptor blockers, n (%) 8 (40) 4 (20) 0.168
ACEI/ARB, n (%) 13 (65) 18 (90) 0.058
Beta blockers, n (%) 13 (65) 13 (65) 1
Statins, n (%) 13 (65) 19 (95) 0.018

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CMR, cardiac magnetic resonance; GRACE, Global Registry of Acute Coronary Events; hsTnT, high‐sensibility troponin T; LVEDVI, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end‐systolic volume index; MVO, microvascular obstruction; PCSK9, proprotein convertase subtilisin/kexin type 9; ST2, soluble interleukin‐1 receptor‐like 1; TIMI, Thrombolysis in Myocardial Infarction.

Values for continuous variables are expressed as mean ± SD unless otherwise specified.

a

Values expressed as median (interquartile range).